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Abstract: Cellular homeostasis depends on robust protein quality control (PQC) pathways that
discern misfolded proteins from functional ones in the cell. One major branch of PQC involves the
controlled degradation of misfolded proteins by the ubiquitin-proteasome system. Here ubiquitin
ligases must recognize and bind to misfolded proteins with sufficient energy to form a complex
and with an adequate half-life to achieve poly-ubiquitin chain formation, the signal for protein
degradation, prior to its dissociation from the ligase. It is not well understood how PQC ubiquitin
ligases accomplish these tasks. Employing a fully reconstituted enzyme and substrate system to
perform quantitative biochemical experiments, we demonstrate that the yeast PQC ubiquitin ligase
San1 contains multiple substrate binding sites along its polypeptide chain that appear to display
specificity for unique misfolded proteins. The results are consistent with a model where these
substrate binding sites enable San1 to bind to misfolded substrates avidly, resulting in high affinity
ubiquitin ligase-substrate complexes.
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All living cells are burdened with the task of disposing of misfolded or damaged
proteins [1]. Termed protein quality control (PQC) [2–7], these molecular pathways guard
against the accumulation of misfolded proteins in cells, which if left unchecked, may result
in the malfunction of normal cellular processes. PQC is especially relevant to human
biology where its breakdown is well known to play roles in the development of various
disease states including neurodegeneration and cancer [8–15]. In eukaryotic cells, the
ubiquitin system, a signal transduction cascade that targets proteins for degradation, is a
major regulator of PQC [16–20]. Here poly-ubiquitin chains are formed onto misfolded proteins bound to ubiquitin ligases, enzymes that scrutinize misfolded proteins from normal
ones [21]. Many mechanistic aspects regarding how PQC ubiquitin ligases function remain
unresolved, such as how misfolded proteins are recognized, and how sufficient binding
energy is achieved to stabilize ligase-substrate complexes that are held together presumably
through weak, nonspecific hydrophobic interactions. Uncovering how ubiquitin ligases
recognize misfolded protein substrates is an important step towards understanding the
molecular pathologies of human diseases that are linked to aberrant PQC processes.
Addressing how ubiquitin ligases bind to and recognize misfolded proteins requires
robust in vitro reconstituted systems that enable biochemical, biophysical, and structural
biological inquiries into function. This is challenging work [22–24] owing to the nature of
misfolded substrates and in at least some cases even the PQC-specific ubiquitin ligases
themselves that collectively contain stretches of solvent-exposed hydrophobic residues
that can lead to aggregation at even relatively low concentrations. Thus, most of the
reconstituted systems in PQC to date require at least some of the components being
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from crude lysate instead of a highly purified source. Nevertheless, amazing progress
has been achieved with fully reconstituted systems in related fields such as molecular
chaperones [25] and inspired our campaign to find a PQC ubiquitin ligase amenable to
in vitro biochemical experiments.
Amongst the best characterized PQC-specific ubiquitin ligases is San1, a Saccharomyces
cerevisiae enzyme that recognizes and ubiquitylates misfolded proteins in the nucleus [26–47].
San1 has several characteristics that imply potential utility for in vitro biochemical experiments. San1 is a modestly sized protein (approximately 65 kDa), and despite it containing
long stretches of disordered regions along the poly-peptide chain, San1 is not known
to oligomerize [45]. A key breakthrough towards a fully reconstituted system was the
development of a small peptide substrate that is ubiquitylated by San1 [37]. Unlike most
misfolded proteins, the peptide substrate displays remarkable solubility, with no visual
precipitation even at concentrations in the low millimolar range, and can be used reproducibly and quantitatively at up to 10 µM in kinetic assays. These properties enabled for
the first time quantitative kinetic assays and new insights into San10 s molecular function.
Perhaps most important is that an understanding of San1 molecular function from assays
performed in yeast cells indicated novel modes of substrate recognition and suggested
biochemical experiments to test these hypotheses.
In a landmark study, the Saccharomyces cerevisiae nuclear PQC ubiquitin ligase San1
was shown to contain multiple contiguous disordered regions in the primary structure that
appear to bind to San1 protein substrates [45], leading to two distinct hypotheses. First,
San1 substrate binding sites may each recognize misfolded protein substrates with little or
even no substrate specificity. On the other hand, San1 substrate binding sites may display
both sequence and structural specificities for substrate. To test these hypotheses, the utility
of the reconstituted San1 PQC ubiquitylation reaction system was significantly improved by
identifying a San1 truncation mutant that is far more amenable to biochemical approaches
and yet recapitulates the in vitro activities of full-length San1. We then demonstrate that
aspects of both hypotheses for San1 substrate binding appear to be valid. While San1
harbors multiple substrate binding sites that seem to recognize distinct substrates, the
evidence also supports the notion that at least some binding sites also bind to the same
substrates. Remarkably, these sites endow San1 with the ability to bind to substrates with
high affinity, suggesting that substrate binding to San1 is driven by an avidity between
substrates and San10 s multiple substrate binding regions.
2. Materials and Methods
2.1. Expression and Purification of Recombinant Proteins
Since wild-type San1 protein has been shown to rapidly auto-ubiquitylate, all experiments performed for these studies were with San1 constructs where lysine residues had
been changed to arginines. Full-length San1 was purified as previously described [37].
San11–303 was purified similarly with a few notable modifications. Briefly, proteins were
expressed in Escherichia coli using Rosetta 2(DE3)pLysS competent cells (Novagen; Gibbstown, NJ, USA). Bacterial cells were grown at 37 ◦ C to an optical density of 0.8–1.0, after
which expression was induced with 0.1 mM IPTG for 2 h followed by centrifugation and
storage of the cell pellets at −80 ◦ C. Bacterial cell pellets were solubilized in lysis buffer
containing 30 mM Tris, pH 7.5, 200 mM NaCl, 5 mM DTT, 1 mM EDTA, 10% glycerol,
and protease inhibitor cocktail (Thermo; Waltham, MA, USA) and disrupted by multiple
rounds of sonication. Lysates were prepared by centrifugation and then incubated with
Glutathione Sepharose 4B beads (GE Healthcare Life Sciences; Chicago, IL, USA) for 3 h at
4 ◦ C. Beads were then collected and washed repeatedly with lysis buffer lacking protease
inhibitors and EDTA. Recombinant GST- San11–303 protein was eluted in a buffer containing
50 mM tris, pH 8.0, 200 mM NaCl, and 40 mM glutathione. The protein was then incubated
with TEV protease overnight at 4 ◦ C, followed by loading onto a 1 mL HisTrap HP column
(GE Healthcare Life Sciences; Chicago, IL, USA) that had been equilibrated in buffer A
containing 50 mM HEPES, pH 7.5, 200 mM NaCl, 20 mM imidazole, and 5% glycerol.
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Histidine-tagged San1 proteins were eluted from the column using a linear gradient of
buffer B containing 50 mM HEPES, pH 7.5, 200 mM NaCl, 300 mM imidazole, and 5%
glycerol. Fractions containing San11–303 were concentrated and then injected onto a Superdex 200 gel filtration column (GE Healthcare; Chicago, IL, USA). Fractions containing
San11–303 were concentrated (Amicon Ultra-4 10,000 NMWL; Burlington, MA, USA) to
approximately 10 µM and flash frozen in liquid nitrogen prior to storage at −80 ◦ C.
Human E1 and Ubc1p were purified as previously described [37]. Recombinant ubiquitin
was purchased from Boston Biochem. Peptide substrates were purchased from New England
Peptide. The peptide amino acid sequences are as shown and with acetylated N-termini.

•
•

San1 peptide N-CGSRRGSYNASSGEQMLSRTGFFLVLIVGQPLHNPVK-Cterm
KR San1 peptide N-CGSRRGSYNASSGEQMLSRTGFFLVLIVGQPLHNPVR-Cterm

2.2. Limited Proteolysis
San1 chymotrypsin digestion assays were performed in a buffer containing 30 mM
Tris, pH 7.5, 100 mM CaCl2 , and 2 mM DTT. All reactions contained 0.25 µM radiolabeled
full-length San1 or San11–303 and were supplemented with 0.1% tween-20. Reactions were
then incubated at room temperature in either the absence or presence of 5 µM San1 peptide
for two minutes followed by the addition of a 1:100 molar ratio of chymotrypsin (SigmaAldrich; St. Louis, MO, USA). Time-points were quenched in 2X SDS-PAGE and boiled for
5 min at 95 ◦ C. Substrate and products were resolved by SDS-PAGE on 4–20% gels, dried,
and exposed on a phosphor screen. Autoradiography was performed using a Typhoon
9410 imager. Quantification of substrate and products were performed with ImageQuant
software (GE Healthcare; Chicago, IL, USA). San1-trypsin digestion assays were performed
similarly except in a buffer containing 30 mM Tris, pH 7.5, 5 mm MgCl2 , 2 mM ATP, 2 mM
DTT, and 0.1% Tween-20 and with a 1:20 molar ratio trypsin to San1. Reactions with Firefly
Luciferase (Sigma-Aldrich; St. Louis, MO, USA) and trypsin were performed similarly as
above except all steps were performed at 42 ◦ C prior to quenching.
2.3. Multi-Turnover Ubiquitylation Reactions
The San1 peptide was radiolabeled (50 µM) in the presence of γ-32 P labeled ATP
(Perkin Elmer; Waltham, MA, USA) and cAMP-dependent Protein Kinase (New England
Biolabs; Ipswich, MA, USA) for 1 h at 30 ◦ C in a reaction buffer that had been supplemented
with tween-20 (0.1%). All reactions were performed in a buffer containing 30 mM Tris,
pH 7.5, 5 mm MgCl2 , 2 mM ATP, 2 mM DTT, and 0.1% Tween-20. Human E1 (1 µM), WT
ubiquitin (60 µM), Ubc1 (10 µM), and either full-length San1 or San11–303 (0.5 µM) were
sequentially added to Eppendorf tubes and incubated for 2 min at room temperature. Next,
3 µM radiolabeled San1 peptide, 3 µM radiolabeled San1 peptide mixed with 3 µM unlabeled San1 peptide, or 3 µM radiolabeled San1 peptide mixed with 6 µM unlabeled San1
peptide were then added to initiate the respective ubiquitylation reactions. Reactions were
quenched at various time-points in 2X SDS-PAGE buffer and substrate and ubiquitylated
products were separated by SDS-PAGE on 4–20% gels (Lonza; Basel, Switzerland). Gels
were dried and exposed to phosphor screens for autoradiography. The quantification of
substrates and products was performed as described in the limited proteolysis section. The
fraction of ubiquitylated San1 peptide was calculated by dividing the amount of peptide
that had been modified by one or more ubiquitins by the total signal in the lane.
2.4. Single-Encounter Ubiquitylation Reactions
All single-encounter reactions were performed in a buffer containing 30 mM Tris, pH
7.5, 5 mm MgCl2 , 2 mM ATP, 2 mM DTT, and 0.1% Tween-20. E1 (1 µM), WT human Ub
(60 µM), and Ubc1 (10 µM) were incubated at room temperature to form activated ubiquitinUbc1 complex (tube 1). In a separate tube, full-length San1 or San11–303 (1 µM) and labeled
San1 Peptide (1 µM) were incubated to form a complex (tube 2). Ubiquitylation reactions
were initiated by mixing tubes 1 and 2 together at room temperature. KR San1 peptide
(10 µM) was added to either tube 1 or tube 2 as a negative control or for single-encounter
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ubiquitylation, respectively. Substrate and products were separated by SDS-PAGE on
4–20% gels, followed by processing and quantification as described in the multi-turnover
ubiquitylation reactions section.
2.5. Nickel Pull-Down
For binding reactions containing peptide substrate, the San1 peptide was radiolabeled
(50 µM) as described in the multi-turnover ubiquitylation reactions section. A total of
5 µM Radiolabeled San1 Peptide was then incubated with 0.1% tween and either 0.5 µM
full-length San1 or KR San11–303 for 5 min at room temperature. Binding reactions were
diluted with 1 mL of nickel wash buffer containing 30 mM Tris, pH 7.5, 250 mM NaCl,
20 mM Imidazole, 0.1% Tween-20, and 5% Glycerol and incubated with 20 µL Nickel-NTA
Agarose beads (Qiagen; Germantown, MD, USA) with gentle agitation for 1 h at room
temperature. Reactions were then spun down at 1000× g for 2 min and 1 mL of additional
wash buffer was introduced to the beads in the absence or presence of 5 µM unlabeled San1
peptide. Reactions were incubated for an additional 2 h under gentle agitation at room
temperature. Beads were spun down and washed twice with wash buffer (containing no
cold peptide). In total, 20 µL of 2X SDS Page buffer was added to the beads and boiled for
5 min at 95 ◦ C. Bead-bound proteins were resolved by SDS-PAGE on 4–20% gels, dried, and
exposed to a phosphor screen to perform autoradiography. The fraction of radiolabeled
substrate bound to the beads was calculated as a fraction of the total input amount.
For binding reactions containing Firefly Luciferase (Sigma Aldrich; St. Louis, MO,
USA), 0.5 µM luciferase was incubated with either 0.5 µM full-length San1 or KR San11–303
for 5 min at 50 ◦ C. Reactions were diluted with 1 mL of warmed nickel wash buffer and
incubated with 20 µL Nickel-NTA Agarose beads with gentle agitation for 1 h at 50 ◦ C.
Reactions were then centrifuged at 3000× g for 30 s and washed three times with warmed
nickel wash buffer. 20 µL of 2X SDS Page buffer was added to the beads and boiled for
5 min at 95 ◦ C. Bead-bound products were transferred to nitrocellulose paper using a
BioRad Semidry Transfer Cell Trans Blot SD and blocked in 5% nonfat milk in TBST for
1 h at room temperature. The membrane was then incubated with anti-luciferase antibody
(Sigma Aldrich; St. Louis, MO, USA) in 0.5% milk using a 1:5000 dilution overnight at 4 ◦ C.
The secondary antibody that had been conjugated to Alexafluor 488 (Invitrogen; Waltham,
MA, USA) was diluted 1:5000 in 0.1% milk and incubated with the membrane for 1 h at
room temperature. Signal was detected using a Typhoon 9410 imager.
2.6. Luciferase Substrate Multi-Turnover Ubiquitylation Reactions
Reactions were performed in a buffer containing 30 mM Tris, pH 7.5, 5 mm MgCl2 ,
2 mM ATP, 2 mM DTT, and 0.1% Tween-20. E1 (1 µM), WT human Ub (60 µM), Ubc1
(10 µM), and either full-length or San11–303 (0.5 µM) were incubated at room-temperature.
In competition reactions, unlabeled KR San1 Peptide (10 µM) was added to the mixture and
incubated for 2 min at 42 ◦ C. Luciferase (0.5 µM) was then added to initiate the reactions
that were then quenched with 2X SDS-PAGE loading buffer at the indicated time points.
Substrate and product were resolved by SDS-PAGE on 4–20% gels. Substrates and products
were transferred to nitrocellulose paper using a BioRad Semidry Transfer Cell Trans Blot
SD and blocked in 5% milk in TBST buffer for 1 h at room temperature. The membrane was
next incubated with anti-luciferase antibody (Sigma Aldrich; St. Louis, MO, USA) in 0.5%
milk and TBST buffer at a 1:5000 dilution overnight at 4 ◦ C. Secondary anti-rabbit antibody
(Sigma Aldrich; St. Louis, MO, USA) diluted 1:5000 in 0.1% milk was incubated with the
membrane for 1 h at room temperature. The membrane was imaged using Western Bright
ECL (VWR; Radnor, PA, USA) on a BioRad ChemiDoc XRS+.
3. Results
We began our investigation by attempting to improve the reconstituted ubiquitylation
system since full-length recombinant San1 protein is highly prone to proteolysis, resulting
in degradation products occurring even after multiple rounds of purification and with
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with affinity-based tags at both the N- and C-terminus (Figure 1A,B). Interestingly the
affinity-based tags at both the N- and C-terminus (Figure 1A,B). Interestingly the major
major San1 degradation product contained an intact N-terminus (Figure 1B). Analysis of
San1 degradation product contained an intact N-terminus (Figure 1B). Analysis of the
the San1 primary sequence suggested that the C-terminus of this fragment may be near
San1 primary sequence suggested that the C-terminus of this fragment may be near the
the Really Interesting New Gene (RING) domain, which recruits activated ubiquitin to the
Really Interesting New Gene (RING) domain, which recruits activated ubiquitin to the
San1-substrate complex. Thus, a construct was generated that expressed the original NSan1-substrate complex. Thus, a construct was generated that expressed the original
terminus of San1 and terminating shortly after the RING domain (1–303). This San1 proN-terminus of San1 and terminating shortly after the RING domain (1–303). This San1
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Figure 1. C-terminal truncation of San1 at the RING domain, San11–303, results in greater purity and homogeneity compared
Figure 1. C-terminal truncation of San1 at the RING domain, San11–303 , results in greater purity and homogeneity compared
with full-length. (A) Coomassie blue-stained SDS-PAGE gel showing the relative purities of full-length San1 versus San11–
with
full-length. (A) Coomassie blue-stained SDS-PAGE gel showing the relative purities of full-length San1 versus
303. Identical amounts of protein were loaded to each lane according to their optical densities at 280 nanometers. Notice
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autoradiography. (C) Ultraviolet absorbance units (UV AU) comparing the migration of full-length San1 and San11–303 by
gel filtration chromatography.
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We hypothesized that if the sites of proteolysis overlap with substrate binding regions,
the addition of substrate may protect San1 from proteolysis. A previously described San1
peptide substrate was employed owing to its unusually high solubility in comparison to
misfolded proteins [37]. Remarkably, a 20-fold molar excess of peptide substrate over San1
resulted in substantial protection of full-length San1 protein in comparison with proteolysis
reactions that lacked substrate (Figure 2A,B).
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Figure 2. Peptide substrate significantly protects both full-length San1 and San11–303 from proteolysis. (A) Representative
autoradiogram of a time-course for untreated, radiolabeled full-length San1 or San11–303 in the presence of chymotrypsin
or in combination with peptide substrate. The migration of full-length San1 is noted by the black arrow on the right;
San11–303 is shown in the rightmost lane (gray arrow). (B) Graph of the results in (A) where the fraction of full-length San1
remaining was normalized to the 15” time-point for the untreated sample (leftmost lane). (C) same as (B), except with
San11–303 . (D) same as (B), except with the protease trypsin. (E) Same as (C), except with the protease trypsin. (F) same as
(D), except with heat-denatured luciferase as substrate. (G) same as (E), except with heat-denatured luciferase substrate.
Representative autoradiograms for the graphs shown in panels (B) through (G) can be found in Figure S1A–E, respectively.
The results all show duplicate data points from technical experimental replicates.
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The stability of San11–303 appeared to be slightly more resistant to chymotrypsin
activity than full-length San1 (Figure 2C and Figure S1A), and the addition of excess peptide
substrate also protected San11–303 from proteolysis. Nearly 50% of San11–303 remained
intact in the presence of chymotrypsin after 30 min, resulting in an approximate 30-fold
increase in the stability of San11–303 protein in comparison with the absence of substrate.
Since the peptide substrate contains residues that are recognized by chymotrypsin, it cannot
be ruled out that at least some amount of San1 protection may be attributed to competition
between San1 and excess peptide substrate for the protease active site. It is also intriguing
to consider whether a chymotrypsin-resistant substrate may result in greater protection of
San1. Similar results were obtained when both full-length San1 or San11–303 were treated
with trypsin (Figure 2D,E and Figure S1B,C). To assess whether a globular, misfolded
protein substrate may protect San1 from proteolysis, heat-denatured luciferase (which had
previously been shown to be ubiquitylated by San1 [37,45]) was added to San1 prior to its
treatment with protease. Both full-length San1 and San11–303 were significantly protected
from trypsin-mediated proteolysis in the presence of misfolded luciferase (Figure 2F,G
and Figure S1D,E). While luciferase, a 64 kDa protein, may be capable of protecting long
stretches of San1 residues from proteolysis, the peptide substrate is only approximately
4 kDa, implying that multiple peptide molecules may be bound to both full-length San1
and San11–303 . In summary, these results support the notion that San1 contains multiple
disordered substrate binding sites.
3.1. San1 Has Multiple High-Affinity Binding Sites for Substrate
To explore whether peptide substrates can simultaneously bind to multiple sites along
full-length San1 as well as San11–303 , multi-turnover kinetics were performed. For fulllength San1, the fraction of substrate converted to ubiquitylated products was highly similar
for all substrate to San1 ratios tested (Figure 3A,B). Some 30% of substrate had become
ubiquitylated after 5 min, and nearly 50% after 15 min, even when substrate was in 18-fold
molar excess of San1. These observations may reflect classical multi-turnover kinetics
where the rapid dissociation of ubiquitylated products from San1 allows for additional
rounds of substrate ubiquitylation during the time course. Alternatively, substrate and
ubiquitylated products may bind tightly to San1 and the existence of additional unoccupied
substrate binding sites would enable similar ratios of substrate conversion to product upon
increasing substrate levels relative to San1.
Multi-turnover ubiquitylation assays were next performing with San11–303 (Figure 3A,B).
Similar to full-length San1, the fraction of substrate that had been converted to product was
consistent for all ratios of substrate to San11–303 . However, the total fraction of substrate
converted to product was approximately 3-fold lower than in comparison with full-length
San1 (Figure 3B). The implications for these observations have been addressed in the
Discussion section. In summary, these results are consistent with either rapid multiturnover kinetics, the existence of multiple peptide substrate binding sites, or a combination
of both.
To distinguish between dynamic substrate binding with San1 or the existence of multiple binding sites, ubiquitylation reactions that were single-encounter between substrate
and San1 were performed with both full-length San1 and San11–303 . A single encounter
between substrate and San1 is achieved by first incubating radiolabeled peptide substrate
with San1 to form the enzyme-substrate complex, followed by the addition of a solution
containing ubiquitin and various enzymes that activate it for transfer to substrate. Excess
unlabeled peptide substrate is then added to the activated ubiquitin solution prior to
initiation of the ubiquitylation reaction that should outcompete radiolabeled substrate and
products that dissociate from San1 (Figure 4A). Ubiquitylation reactions were first performed in the absence of unlabeled competitor substrate, resulting in robust ubiquitylation
of radiolabeled peptide substrate (Figure 4B, lanes 1–3, and Figure 4C).
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Multi-turnover ubiquitylation assays were next performing with San11–303 (Figure
Negative
experiments
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full-length
San1
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3A,B).
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strate.
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no substrate
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the ability
of unlaof substrate
to ubiquitylation
product was approximately
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Figure
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San1 (Figureradiolabeled
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for these
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been4C).
adRemarkably,
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reaction,
the
fraction
of
substrate
converted
to
ubiquidressed in the Discussion section. In summary, these results are consistent with
either
tylated
products was nearly
identical
in comparison
withpeptide
the positive
control
reaction
at all
rapid multi-turnover
kinetics,
the existence
of multiple
substrate
binding
sites,
or
three
time-points
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(Figure
4B,
lanes
7–9,
and
Figure
4C).
Highly
similar
results
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oba combination of both.
servedTo
for
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between
peptide
substrate
and San1
(Figureof
4D,E).
1–303
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dynamic
substrate
binding
with San1
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mulIn
summary,
these
results
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suggest
that
the
peptide
substrate
as
well
as
ubiquitiple binding sites, ubiquitylation reactions that were single-encounter between substrate
tylated
products
remain tightly
to both full-length
San1
and
to San11–303encounter
over the
and San1
were performed
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time
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next
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andaddition
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ofHere
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and
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first
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containing ubiquitin and1–303
various enzymes that activate it for transfer to substrate. Excess
subsequently immobilized onto nickel-agarose beads followed by washing (Figure 5A).
unlabeled peptide substrate is then added to the activated ubiquitin solution prior to iniDespite a two hour incubation period with wash buffer, radiolabeled substrate remained
tiation of the ubiquitylation reaction that should outcompete radiolabeled substrate and
bound to both full length San1 and San11–303 (Figure 5B,C). However, the addition of
products that dissociate from San1 (Figure 4A). Ubiquitylation reactions were first perexcess unlabeled substrate peptide to the wash buffer resulted in substantial dissociation
formed in the absence of unlabeled competitor substrate, resulting in robust ubiquitylaof labeled substrate from bead-bound San1 to levels comparable with negative control
tion of radiolabeled peptide substrate (Figure 4B, lanes 1–3, and Figure 4C).
pull-downs that lacked San1 (Figure 5B,C). Nickel pull-downs with full-length San1 or
San11–303 and heat-denatured luciferase substrate also resulted in tight binding that was
highly resistant to stringent washing conditions, demonstrating that San1 binds to both a
small peptide as well as a misfolded globular protein with high affinity.
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addition of excess unlabeled substrate peptide to the wash buffer resulted in substantial
dissociation of labeled substrate from bead-bound San1 to levels comparable with negative control pull-downs that lacked San1 (Figure 5B,C). Nickel pull-downs with full-length
San1 or San11–303 and heat-denatured luciferase substrate also resulted in tight binding that
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was highly resistant to stringent washing conditions, demonstrating that San1 binds to
both a small peptide as well as a misfolded globular protein with high affinity.

Figure
5. Peptide
substrate
to high
San1affinity.
with (A)
high
affinity.
(A) Schematic
showing
a nickelFigure
5. Peptide
substrate
is boundistobound
San1 with
Schematic
showing
a nickel-pulldown
assay
to assess
the
strength
of
the
San1-peptide
substrate
complex.
(B)
Representative
autoradiogram
of
the
results
of
the
nickel-pulldown
pulldown assay to assess the strength of the San1-peptide substrate complex. (B) Representative
assay. (C) Graphical representation of the results shown in panel (B). The results show duplicate data points from technical
experimental replicates. (D) same as (B) except with heat-denatured luciferase protein substrate.
3.2. San1 Substrate Binding Sites Display Specificity
Having established that San1 forms a tight complex with substrates, we next addressed
whether San1 substrate binding sites display substrate specificity. Ubiquitylation reactions
were performed with heat-denatured luciferase substrate and in the presence or absence
of competitor peptide substrate (KR San1 peptide). Full-length San1 or San11–303 were
pre-incubated with unlabeled competitor peptide substrate followed by the addition of
heat-denatured luciferase and activated ubiquitin. Surprisingly, luciferase was strongly
ubiquitylated despite the presence of competitor peptide (Figure 6). Indeed, the fraction
of luciferase converted to ubiquitylated products was comparable with positive control
reactions lacking competitor peptide. These results strongly contrast with the singleencounter reactions (Figure 4), supporting the notion of San1 having multiple substrate
binding sites that have the capacity to display specificity.
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An intriguing observation from the kinetic experiments is that the fraction of peptide
substrate converted to ubiquitylated product was consistent for both full-length San1
and San11–303 over a very broad range of substrate concentrations (Figure 3). Indeed,
nearly 50% of substrate was converted by full-length San1 to product, suggesting that, on
average some nine substrate peptides were bound to San1 at the highest ratio of substrate
to ubiquitin ligase (18:1). However, only 15% of substrate was converted to product with
San11–303 over the same incubation period and the same substrate to ligase ratio. What
can be gleaned from these observations regarding San10 s mechanism? In our model, when
substrate levels are low, only the highest affinity binding sites are occupied to promote
substrate ubiquitylation. The titration of substrate concentrations to higher levels leads
to additional sites being occupied until eventually saturation is achieved. However, note
that saturation was not achieved here even at the maximal substrate to San1 ratio (18:1)
for full-length San1 or for San11–303 . The model also suggests why San11–303 converts a
lower fraction of substrate to product than full-length. The truncation of the C-terminus to
the RING domain seems to have deleted at least some of the binding sites for the peptide
substrate, although alternative explanations cannot be ruled out since the peptide solubility
is insufficient to achieve saturation of either San1 protein.
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Our model also explains why San1 appears to have such remarkable affinity for
substrates. The existence of multiple substrate binding sites along a disordered polypeptide chain is likely to result in their achieving proximity with each other. The random
coalescing of these binding sites is conceptually similar to the principle of how other
avidity-dependent binding events such as affinity chromatography occur. San1 shows avid
binding to substrate since the dissociation of a substrate from San1 would likely result in
rapid rebinding owing to the high local concentration of unoccupied binding sites. Additionally, similar to affinity chromatography, one means for disrupting the San1-substrate
complex is through the addition of excess substrate which was observed during the nickel
pull-down binding studies reported here.
Our results stand in striking contrast with how more typical ubiquitin ligases create binding energy with their substrates. For instance, the cullin-RING ligases are the
largest and perhaps best characterized family of ubiquitin ligases to date [48]. Here, substrate specificity and affinity are afforded by highly specific inter-molecular interactions
between ubiquitin ligase and substrate, leading to sub-micromolar equilibrium dissociation
constants. However, consider that the half-life of a typical cullin-RING ligase-substrate
complex is only a few seconds [49], in contrast with the results presented here where
the half-life is orders of magnitude longer. Under this scenario where the cullin-RING
ligase-substrate complex is fleeting, a minor but significant fraction of substrate will dissociate from the ubiquitin ligase prior to its ubiquitylation. Thus, these aborted complexes
need at least one more round of substrate binding to the ubiquitin ligase for a chance at
achieving ubiquitylation. For the cullin-RING ligases, this may delay ubiquitylation by
seconds. However, due to the aggregation-prone nature of PQC substrates, even their
fleeting existence in the cell may be detrimental to its survival. Thus, PQC ubiquitin ligases
may act like molecular fly paper, binding very tightly to their substrates to prevent their
aggregation. Interestingly, it has been shown that some PQC substrates rely on a AAA ATPase called Cdc48 (p97 in humans) to promote ubiquitylation and/or degradation [31,36].
It is tempting to speculate that Cdc48 dependency may also be important to help dissociate
tightly bound ubiquitylated substrates from San1.
Like all investigations, our results point to additional experiments that are necessary
to further unravel the mechanism of how PQC ubiquitin ligases recognize and bind to
misfolded protein substrates. Nevertheless, the results demonstrate how a PQC-specific
ubiquitin ligase has evolved an apparently unique mechanism in comparison with more
typical ligases for establishing tight substrate binding, and we sincerely hope that these
results will embolden other researchers in the field to further develop quantitative in vitro
assays for San1 as well as for their PQC-specific ubiquitin ligases of interest. It is also our
hope that the demonstration that San11–303 is possibly amenable to sophisticated in vitro
experiments will lead to more quantitative assays as well as perhaps structural biological
efforts, as we consider these prerequisite before a detailed molecular understanding of
PQC ubiquitylation can be achieved.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/biom11111619/s1, Figure S1: Peptide substrate significantly protects both full-length San1
and San11–303 from proteolysis.
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